Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2018-09-03 Regulatory Filings
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
BioArctic expands the research collaboration with Uppsala University concerning antibody-based diagnostic imaging of the brain in Alzheimer patients
Regulatory Filings Classification · 1% confidence The document is titled 'Press release' and announces an expansion of a research collaboration agreement between BioArctic and Uppsala University regarding diagnostic imaging for Alzheimer's patients. It details the terms (financial support for a research position) and the scientific context. It concludes with boilerplate information about Alzheimer's disease and the company, and a statement regarding EU Market Abuse Regulation disclosure. This type of announcement, detailing a specific business development (research agreement expansion) that is material to investors but is not a formal financial report (like 10-K, IR, or ER), typically falls under general regulatory announcements or news releases. Since it is a specific business update that doesn't fit the other specialized categories (like M&A, Capital Change, Dividend, or Director Dealing), the most appropriate classification is the general regulatory/news fallback category, RNS (Regulatory Filings). The document length is short (under 5,000 characters) and it is a direct announcement, not a report itself, confirming it is not RPA.
2018-09-03 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for BioArctic AB covering the period January to June 2018. It contains comprehensive financial statements, management commentary (VD har ordet), project portfolio updates, and notes. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis for a period shorter than a full fiscal year. H1 2018
2018-08-23 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report January – June 2018' and contains comprehensive financial statements, including income statements, cash flow data, and balance sheet metrics for the specified period. It also includes a CEO statement, project portfolio updates, and financial summaries. Since it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). H1 2018
2018-08-23 English
Invitation to presentation of BioArctic’s Interim Report for the period January – June 2018 on August 23, 2018
Report Publication Announcement Classification · 1% confidence The document is a press release dated August 14, 2018, announcing the upcoming publication of BioArctic's 'Interim Report for the period January – June 2018' on August 23, 2018. It also invites stakeholders to an audiocast/teleconference to discuss this report. Since the document is an announcement about the release of a financial report (the Interim Report) rather than the report itself, and it provides details about the presentation/call, it fits the definition of a Report Publication Announcement (RPA). The document length (2409 chars) is short, supporting the RPA classification over the full Interim Report (IR) classification.
2018-08-14 English
Inbjudan till presentation av BioArctics delårsrapport för perioden januari – juni 2018 den 23 augusti 2018
Report Publication Announcement Classification · 1% confidence The document is a press release titled "Inbjudan till presentation av BioArctics delårsrapport för perioden januari – juni 2018" (Invitation to the presentation of BioArctic's interim report for the period January – June 2018). It announces the publication date (August 23, 2018) and time for the interim report and invites stakeholders to an audiocast/conference call to discuss this report. Since the document's primary function is to announce the upcoming release of a financial report (an interim report) and invite participation in the subsequent discussion, it fits the definition of a Report Publication Announcement (RPA). It is not the interim report itself (which would be 'IR') nor the transcript of the call ('CT'). The document length (2414 chars) is short, supporting the RPA classification based on the 'MENU VS MEAL' rule.
2018-08-14 Swedish
BioArctic obtains exclusive rights to develop antibody treatments for Alzheimer’s disease from a research project jointly owned with Eisai
Regulatory Filings Classification · 1% confidence The document is titled 'Press release' and announces a significant business development: BioArctic obtaining exclusive rights from Eisai for developing antibody treatments for Alzheimer's disease based on a joint research project. This involves changes in commercial rights and strategic focus, but it is not a standard regulatory filing like a 10-K, an earnings release (ER), or a formal capital structure change (CAP/SHA). It is a specific announcement regarding strategic partnership terms and asset rights. Since it details a major business/licensing agreement that impacts the company's future development pipeline, it most closely aligns with a general corporate announcement that doesn't fit the highly specific categories like M&A (TAR) or Director's Dealing (DIRS). Given the options, this type of strategic corporate action announcement, especially one related to licensing/development rights, is best categorized as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard corporate news, or potentially a Capital/Financing Update (CAP) if the rights acquisition involved a significant upfront payment, but the text focuses purely on the rights transfer. Since it is a press release announcing a strategic agreement, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback category when specific categories like M&A or Financing are not explicitly met.
2018-08-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.